



Year-end report 2019

Press and analyst presentation

6 February 2020

Per Strömberg, CEO Sven Lindskog, CFO

In brief

Good conclusion to a strong year

Continued strong online sales growth

Launch of new loyalty program in Sweden






Solid development

- Net sales growth adjusted for Hemtex divestment,+3.8%
- Net sales up in local currency, +2.2%
- Solid EBIT and margin development

F	V	6	n	ts

- Ramp-up of Apotek Hjärtat warehouse in Norrköping back on track, improved efficiency
- Rimi Baltic e-commerce launch
- Launch of new loyalty program in Sweden
- Lena Boberg, CEO of ICA Real Estate, leaves by the summer
- The board proposes dividend of 12.00 SEK/share

MSEK	Q4 2019	Q4 2018	Change %
Net sales	30,850	30,069	2.6
EBIT	1,267	1,180	7.3
EBIT Margin	4.1%	3.9%	0.2 pp



EBIT equals "EBIT excluding items affecting comparability" on all slides in this presentation.



ICA SWEDEN

Store sales growth in line with market, positive volume growth

Store sales and market in Q4

ICA store sales growth of +3.7%, comparable stores +3.5%


Higher average buy

Price and calendar effect +3.1% (price effect +3.1%, calendar effect +0%).

Market growth according to DVI +3.7%

ICA Online sales growth +25% (food online +30%, menu baskets -3%). Market growth (DVI) +17%

Establishments Q4: 5 new stores



DVI=Dagligvarubutiksindex/Food Retail Index which includes grocery sales in stores and online



Sales growth below market

Store sales and market in Q4

Rimi store sales +2.6%, comparable sales +0.9%

- Comparable store sales:
 - Estonia +0.7%
 - Latvia +0.1%
 - Lithuania +2.8%
- Rebranding est. impact on growth -1.1%


Market growth +4.3%

- Estonia +5.1%
- Latvia +4.1%
- Lithuania +4.0%

Food inflation +2.7%

- Estonia +1.1%
- Latvia +2.9%
- Lithuania +3.4%

Establishments Q4: 7 new stores





APOTEK HJÄRTAT

Sales above market growth – driven by prescription sales

Store sales and market in Q4

Apotek Hjärtat store sales growth +3.0% (excl. Minutkliniken +3.1%)


- Prescription +3.3%
- OTC +0.3%
- Traded goods +3.2% (excl. Minutkliniken +3.7%)

Market growth of +2.7%

- Prescription +1.7%
- OTC +2.2%
- Traded goods +7.1%

Online sales growth Apotek Hjärtat +37%, market +32%

Establishments in Q4: 2 new pharmacies





Highlights



Our strategic picture

- where we want to be







Closer to our customers

We are where our customers are, locally, digitally and personally, with strong and affordable customer offerings



Trusted & relevant

We earn our customers' loyalty with a great brand, a broad ecosystem and personalised, data driven communication





Empowered organisation

We are committed and inclusive. Together we build a fast moving and constantly learning company



Always better

We improve continuously and leverage technology to make it easier for our customers, improve efficiency and value for money



A positive force

We lead the development towards a more sustainable and healthy society – for a good tomorrow



Our new loyalty program interacts in a more personal and relevant way with the customer...



From transaction based to more customer based, with a personal and simple tone – "like a store owner"

Will drive a more loyal behaviour over time

More relevant, valuable and personal for the customer

Identification of the customer with any payment card

Some adjustments made to bonus levels due to customer feed-back








... and will further enable us to strengthen and

utilize ICA Gruppen's ecosystem







New target to be set in 2020

climate beyond neutrality

Decrease in emissions compared with 2006

-67%

Socially audited suppliers of corporate brands in high-risk countries

95%

Vs. goal of 100%

Quality certified suppliers of corporate brands

87%

Vs. goal of 90%

We will be climate neutral 2020

 New target to be set during 2020 – climate beyond neutrality, an increased ambition from today's goal

- New plastic packaging for fresh private label meat
 - Reduces the use of plastics by 60 tonnes annually
 - 250 tonnes plastics annually will be replaced by recycled plastics





Financials



Robust EBIT development

Net sales +2.6%

- Adjusted for Hemtex, +3.8%
- Growth in local currency +2.2% largely price, but also volume growth in ICA Sweden, Apotek Hjärtat and ICA Bank

EBIT improving across most segments

- Gross margins stronger
- Investments in e-commerce and digitalisation continues

Cash flow lower – mainly calendar effects

EPS slightly up

MSEK	Q4 2019	Q4 2018	Change %
Net Sales	30,850	30,069	2.6
EBIT	1,267	1,180	7.3
EBIT margin %	4.1%	3.9%	0.2 pp
Cash flow ¹	2,925	3,648	-19.8
Earnings per share (SEK)	4.52	4.42	2.3

¹ Cash flow from operating activities excl. ICA Bank





EBIT variance analysis Q4 (estimate)

	MSEK
EBIT Q4 2018	1,180
Sales Volume	5
Margin	256
Store costs	-72
Other costs	-113
Revised useful lives of fixed assets	17
Acquisition/Divestment related effects	-68
Structural costs and one-off items	60
EBIT Q4 2019	1,267





Growing sales and stable margins

Net sales growth +3.1%

- Price, increased wholesale volume
- Online growth

Underlying EBIT slightly above last year

- + Price and wholesale volume growth
- + Gross margin in aggregate stable
- One-offs MSEK 60, (LY MSEK 110, current year MSEK 50), organisational and closure of stores this quarter
- Business development costs digitalisation and e-commerce

MSEK	Q4 2019	Q4 2018	Change %
Net sales	22,020	21,348	3.1
EBIT	827	750	10.3
EBIT Margin	3.8%	3.5%	0.2 pp





RIMI BALTIC

Continued EBIT and margin improvements

- Net sales growth in local currency +2.0%, mainly price
- Impact from store conversions in Latvia

Strong EBIT improvement and margin

- + Price/mix effects
- Improved PL margin and campaign efficiency
- + Logistic costs, improved efficiency
- Salary inflation in logistics and stores
- Store costs and marketing

MSEK	Q4 2019	Q4 2018	Change %
Net sales	4,279	4,066	5.2
EBIT	213	182	17.2
EBIT Margin	5.0%	4.5%	0.5 pp





APOTEK HJÄRTAT

Recovering after automation issues in Q3

Sales growth +4.7%

 Positive effect from price, online growth and new pharmacies

EBIT and EBIT margin lower

- + Price/mix
- Costs related to automation disturbances in Norrköping, MSEK 10
- Investments in e-commerce, business development and IT
- Min Doktor EBIT effect MSEK -15 vs LY

MSEK	Q4 2019	Q4 2018	Change %
Net sales	3,813	3,641	4.7
EBIT	117	128	-8.6
EBIT Margin	3.1%	3.5%	-0.4 pp





ICA REAL ESTATE

Stable progress


Net sales higher

 Increased net sales from acquisitions and other investments made during the year

Improved EBIT

- + Increased income from new investments
- + Revised estimates of the useful life of fixed assets. "One-off" effect Q4 MSEK 17 (FY effect approx. MSEK 60)
- Operating costs somewhat higher

MSEK	Q4 2019	Q4 2018	Change %
Net sales	688	658	4.5
whereof owned properties	277	263	5.0
Net Yield	6.8%	6.8%	0.0 pp
EBIT	126	115	9.6
EBIT Margin	18.3%	17.4%	0.8 pp





Steady growth and solid EBIT progress

Continued good growth in net income

- Customer loans and mortgages
- Continued growth in ICA Insurance, >178,000 customers

Strong EBIT improvement

- + Volume growth, loans and insurances
- + Net interest higher repo rate
- + Lower costs
- + Improving claims ratio
- Slightly higher credit losses

MSEK	Q4 2019	Q4 2018	Change %
Net income	410	358	14.5
EBIT	74	42	75.7
Business Volume	50,515	46,618	8.4






Calendar impact reduces Q4 cash-flow

Operating cash-flow lower than LY:

- Negative calendar effects in WC development, following a very strong Q3
- EBIT up
- Paid tax lower








Net debt down

Net debt improving with underlying cashflow

Net debt ratio 2.0x, with high impact from IFRS16 accounting

IRFS16 adds SEK 15.9 billion to net debt as per Q4 2019







Long term financial targets

Targets	R12 (31 Dec 2019), %	Long-term targets, %
Grow faster than market ¹	Sweden Sweden Baltics Pharmacy	All markets
EBIT margin excl. non-recurring items	4.5	4.5
ROCE ²	7.9	7.5
Net debt/EBITDA ³	2.0x	<3.0x
Dividend ⁴ (% profit of the year 2019)	70	At least 50

The changeover to IFRS 16 impacts EBIT margin, ROCE, Net debt/EBITDA and dividend ratio



¹ Swedish and Baltic growth based on latest definitive market data Q4, 2019

² Excluding ICA Bank

³Interest-bearing liabilities excluding pensions and ICA Bank minus cash and cash equivalents in relation to EBITDA, operating income before depreciation and impairment

⁴ Dividend proposed by the board to be decided by the AGM 21 April 2020

Outlook and Summary



Outlook



ICA Sweden

- Leveraging new organisation
- Continued investments in digitalisation and business development
- Continued ramp-up of e-commerce warehouse and establishing new ecommerce warehouses
- 8-10 store openings in 2020 with focus on large cities

ICA Real Estate

 Increase our presence in metropolitan areas through land and property banking

Rimi Baltic

- Extract further cost efficiencies within distribution and store operation
- Progress on digital initiatives (online shopping, self-service check-out, self scanning, etc)
- Extend assortment of convenience and meal solutions in Rimi Express
- Investing in preparations for Lidl entry
- 16-18 store openings in 2020

ICA Bank

- Set-up of new mortgage joint venture
 - Short term negative impact on mortgage commissions during transition phase
- Increased repo rate positive for 2020
- ICA Insurance growth focus continues

Apotek Hjärtat

- Gradual recovery
- Continued focus on realising efficiency in automated warehouse in Norrköping
- Further investments in digital initiatives, online and last mile
- 6-8 new pharmacies in 2020

ICA Gruppen

Group costs guidance MSEK 450 FY



In brief

Good conclusion to a strong year

Continued strong online sales growth

Launch of new loyalty program in Sweden





Thanks!

2020-02-06



Disclaimer

This information is such that ICA Gruppen AB is obligated to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication February 6 2020 at 7.00 CET.

This report contains forward-looking statements that reflect the Board of Directors' and management's current views with respect to certain future events and potential financial performance. Although the Board of Directors and the management believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of, among other factors, (i) changes in economic, market and competitive conditions, (ii) success of business and operating initiatives, (iii) changes in the regulatory environment and other government actions, (iv) fluctuations in exchange rates and (v) business risk management.

This report does not imply that the Company has undertaken to revise these forward-looking statements, beyond what is required under the company's registration contract with Nasdaq Stockholm, if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

